logo
This cutting edge hair loss treatment is a repurposed drug from the 1990s

This cutting edge hair loss treatment is a repurposed drug from the 1990s

Yahoo19-03-2025

WASHINGTON (AP) — The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the 1990s.
Back then, TV viewers were inundated with ads for Rogaine, a sticky topical solution that could help treat thinning hair when applied to the scalp.
Now dermatologists are increasingly prescribing the drug, known generically as minoxidil, in low-dose pills to help men and women maintain or regrow hair.
The practice follows a handful of recent studies suggesting the ingredient works as well — and possibly better — when swallowed, rather than applied to hair follicles on the head. Telehealth companies are also driving new demand by offering a quick, easy way to get a prescription and have the pills shipped directly to customers' doors.
Here's a look at the drug:
A retro approach to hair loss
Minoxidil was originally developed as a pill to treat high blood pressure in the 1970s. Researchers noticed that some patients taking it experienced increased hair growth as a side effect.
Rogaine was approved by the Food and Drug Administration in 1988, the first drug to win the agency's endorsement for male pattern baldness. Studies showed that men on the medication, which was applied directly to the scalp, had a slower rate of hair loss and, in some cases, regrew hair.
Starting in 1991, a lower dose was approved for women and the brand was aggressively marketed as an over-the-counter medication on TV and in print.
The drug's ability to slow hair loss is likely related to its effect on blood circulation, according to experts.
'By increasing blood flow to the scalp it signals hairs to stay in their grow phase for longer,' said Dr. Adam Friedman, chair of dermatology at George Washington University. 'We're trying to keep those hairs in that growth phase as long as possible.'
A recent consensus paper by more than 40 U.S. and international dermatologists concluded that minoxidil pills are effective and often more convenient and affordable than the liquid formulation.
Patients prefer the pill
There's little research comparing the two forms of minoxidil, but many dermatologists believe the drug works better as a pill.
At a chemical level, minoxidil is absorbed more directly when digested in the gut than when applied to the hairline. It's also more convenient, with patients taking the drug by mouth once a day, instead of applying the liquid once or twice daily using a dropper.
'As you can imagine, that can be rather onerous,' said Dr. Susan Taylor of the University of Pennsylvania. 'Although people often enthusiastically begin therapy— and even see results — after a while there are many who drop off.'
The doses prescribed for oral use are also very low. Dermatologists often direct men to take one half of the lowest-dose pill; women may only need a quarter of a pill.
Those low doses can also reduce the chances for side effects, which can include dizziness, rapid heartbeat and swollen legs. The drug isn't recommended for people with a history of heart issues or who are pregnant or breastfeeding.
The only other FDA-approved medication for hair loss is finasteride, sold under the brand name Propecia, a drug that blocks a byproduct of testosterone that triggers hair loss in men. That drug is generally considered more effective than minoxidil, but it can occasionally cause troubling sexual side effects, including erectile dysfunction. For optimal results, some dermatologists prescribe the two drugs in combination.
Why aren't minoxidil pills FDA-approved for hair loss?
In short, because there's very little money to be made.
Minoxidil's patent has expired and it is now available as a low-cost generic medication. That means drugmakers have little financial incentive to spend millions on the new studies that would be needed to win FDA approval for hair loss.
'For a drug like oral minoxidil — which is as old as dirt at this point — there are no reasons to do that,' said Friedman. Like other dermatologists, Friedman gives hair-loss patients a prescription for the pills intended to treat blood pressure, a practice known as off-label prescribing.
The upside for patients is that minoxidil is extremely affordable, with some pharmacies offering a month's supply for less than $5.
'Not a single patient has complained to me about the cost of this medication, which is extremely rare,' said Dr. Luiz Garza of Johns Hopkins University.
Telehealth firms open up access
The vast majority of doctors prescribing minoxidil for hair loss are dermatologists, who often turn to older drugs off-label for various hair and skin conditions.
A survey of U.S. dermatologists published last year found 80% reported prescribing oral minoxidil. But with only about 12,000 dermatologists in the U.S., some patients may have trouble finding a provider.
Telehealth providers like Hims and Ro say they are helping fill the gap. The companies' business model offers patients quick access to the medications they are seeking, often after simply filling out a questionnaire about their medical history, medications and treatment goals. The information is reviewed by a health provider who can quickly approve a prescription, assuming there are no red flags.
Hims and Ro each say that their providers won't prescribe minoxidil for patients who have complicating health conditions or prescriptions that could negatively interact with the drug. In some cases, patients may be referred for an office visit.
Many dermatologists say patients are better served by an in-person appointment, where a doctor will usually take a blood pressure reading, evaluate medical history, prescriptions and discuss the drug's side effects.
'I'm not a proponent of going to an online service,' said Taylor. 'I recommend seeing your board-certified dermatologist who's trained, who knows the data and can evaluate all of you.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Real Madrid star Kylian Mbappe hospitalized with gastroenteritis at the Club World Cup
Real Madrid star Kylian Mbappe hospitalized with gastroenteritis at the Club World Cup

Fox Sports

time18 minutes ago

  • Fox Sports

Real Madrid star Kylian Mbappe hospitalized with gastroenteritis at the Club World Cup

Associated Press MIAMI (AP) — Real Madrid forward Kylian Mbappe has been hospitalized with an acute case of gastroenteritis, the Spanish club said Thursday. World Cup winner Mbappe missed Madrid's opening game at the Club World Cup against Saudi Arabian team Al Hilal in Miami on Wednesday because of a fever. Coach Xabi Alonso said he hoped the France international would be available for the team's next game against Pachuca on Sunday. But his hospitalization casts doubt over what part he might be able to play in the monthlong tournament in the United States. 'Our player Kylian Mbappé is suffering from an acute case of gastroenteritis and has been admitted to hospital in order to undergo a series of tests and follow the appropriate course of treatment,' Madrid said in a statement. ___ James Robson is at ___ AP soccer: in this topic

Struggling With Hair Loss? This New Prescription Gummy Could Help Regrow It
Struggling With Hair Loss? This New Prescription Gummy Could Help Regrow It

CNET

timean hour ago

  • CNET

Struggling With Hair Loss? This New Prescription Gummy Could Help Regrow It

You've tried the serums, the vitamins and the topical solutions. But have you tried a prescription gummy for hair loss? Hers, a telehealth company that provides online healthcare services and products for women, announced the launch of its Biotin plus Minoxidil Gummy, the first-of-its-kind prescription gummy formulated to support hair regrowth. Available through this gummy combines prescription-strength minoxidil, the only FDA-approved ingredient for female hair loss, with biotin, a popular vitamin for supporting healthy skin, hair and nails. Minoxidil is clinically proven to regrow thicker, fuller hair in three to six months (based on studies of oral minoxidil up to 2.5 mg per day at various doses). It's the first prescription hair regrowth gummy to hit the market, and it offers women a more convenient way to stay consistent with treatment, something Hers chief medical officer and OB-GYN Dr. Jessica Shepherd says is often overlooked in traditional regimens. "The gummy is a once-daily dose that's designed to help women stick to their prescribed hair regimens as deemed clinically necessary by their provider to address their individual needs," she says. Hers Shepherd told CNET that everything about the product, from the packaging to the vegan formula to the taste (green apple flavor) and texture, was crafted with women's preferences in mind. The goal is a treatment that feels more like a self-care ritual than a chore. Why a gummy? Unlike traditional pills or topicals, the Biotin plus Minoxidil Gummy was formulated with adherence in mind. The proprietary compounded formula allows providers to personalize each prescription to individual needs, including adjusting the dosage to minimize side effects or combining multiple ingredients to tackle various concerns simultaneously. "By leveraging the power of personalization, we're making it possible for women to access treatment designed to address their individual needs for their unique body, lifestyle and goals. This is the benefit of compounding," says Shepherd. How much does it cost, and where can I get it? The Biotin plus Minoxidil Gummy is available through Hers after a virtual consultation with one of its licensed providers. Each prescription is customized based on your unique hair loss patterns and goals. Hers strives to offer patients affordable treatments without insurance (no insurance is accepted), and the gummies start at $35 per month. To learn more or schedule a consultation, visit

Israel threatens Iran's top leader after missiles damage hospital and wound more than 200
Israel threatens Iran's top leader after missiles damage hospital and wound more than 200

Politico

time2 hours ago

  • Politico

Israel threatens Iran's top leader after missiles damage hospital and wound more than 200

BEERSHEBA, Israel (AP) — Israel's defense minister overtly threatened Iran's supreme leader on Thursday after the latest missile barrage from Iran damaged the main hospital in southern Israel and hit several other residential buildings near Tel Aviv. Israel meanwhile struck a heavy water reactor that is part of Iran's nuclear program. At least 240 people were wounded by the Iranian missiles, four of them seriously, according to Israel's Health Ministry. The vast majority were lightly wounded, including more than 70 people from the Soroka Medical Center in the southern city of Beersheba, where smoke rose as emergency teams evacuated patients. In the aftermath of the strikes, Israeli Defense Minister Israel Katz blamed Iran's Supreme Leader Ayatollah Ali Khamenei and said the military 'has been instructed and knows that in order to achieve all of its goals, this man absolutely should not continue to exist.' U.S. officials said this week that President Donald Trump had vetoed an Israeli plan to kill Khamenei. Trump later said there were no plans to kill him 'at least not for now.' Israel carried out strikes on Iran's Arak heavy water reactor, in its latest attack on the country's sprawling nuclear program. The conflict began last Friday with a surprise wave of Israeli airstrikes targeting military sites, senior officers and nuclear scientists. A Washington-based Iranian human rights group said at least 639 people, including 263 civilians, have been killed in Iran and more than 1,300 wounded. In retaliation, Iran has fired over 400 missiles and hundreds of drones, killing at least 24 people in Israel and wounding hundreds. Two doctors told The Associated Press that the missile struck almost immediately after air raid sirens went off, causing a loud explosion that could be heard from a safe room. They spoke on condition of anonymity because they were not authorized to brief media. The hospital said the main impact was on an old surgery building that had been evacuated in recent days. After the strike, the medical facility was closed to all patients except for life-threatening cases, it said. Soroka has over 1,000 beds and provides services to around 1 million residents of Israel's south. There were no serious injuries from the strike on the hospital. Israeli Prime Minister Benjamin Netanyahu condemned the attack and vowed a response, saying: 'We will exact the full price from the tyrants in Tehran.' Iran has fired hundreds of missiles and drones at Israel, though most have been shot down by Israel's multi-tiered air defenses, which detect incoming fire and shoot down missiles heading toward population centers and critical infrastructure. Israeli officials acknowledge it is imperfect. Many hospitals in Israel activated emergency plans in the past week, converting underground parking to hospital floors and moving patients underground, especially those who are on ventilators or are difficult to move quickly. Israel also boasts a fortified, subterranean blood bank that kicked into action after Hamas' Oct. 7, 2023 attack ignited the ongoing war in the Gaza Strip. Israel's military said its fighter jets targeted the Arak facility and its reactor core seal in order to prevent it from being used to produce plutonium. 'The strike targeted the component intended for plutonium production, in order to prevent the reactor from being restored and used for nuclear weapons development,' the military said. Israel separately claimed to have struck another site around Natanz it described as being related to Iran's nuclear program. Iranian state TV said there was 'no radiation danger whatsoever' from the attack on the Arak site. An Iranian state television reporter, speaking live in the nearby town of Khondab, said the facility had been evacuated and there was no damage to civilian areas around the reactor. Israel had warned earlier Thursday morning it would attack the facility and urged the public to flee the area. Iran has long maintained its program is for peaceful purposes. However, it also enriches uranium up to 60%, a short, technical step away from weapons-grade levels of 90%. Iran is the only non-nuclear-weapon state to enrich at that level. Israel is the only nuclear-armed state in the Middle East but does not acknowledge having such weapons. The strikes came a day after Iran's supreme leader rejected U.S. calls for surrender and warned that any military involvement by the Americans would cause 'irreparable damage to them.' Israel had lifted some restrictions on daily life Wednesday, suggesting the missile threat from Iran on its territory was easing. Already, Israel's campaign has targeted Iran's enrichment site at Natanz, centrifuge workshops around Tehran and a nuclear site in Isfahan. Its strikes have also killed top generals and nuclear scientists. Iran's Foreign Minister Abbas Araghchi said he would travel to Geneva for meetings with his European counterparts on Friday, indicating a new diplomatic initiative might be taking shape. Iran's official IRNA news agency said the meeting would include foreign ministers from the United Kingdom, France and Germany and the European Union's top diplomat. Trump has said he wants something 'much bigger' that a ceasefire and has not ruled out the U.S. joining in Israel's campaign. Iran has warned of dire consequences if the U.S. deepens its involvement, without elaborating. The Arak heavy water reactor is 250 kilometers (155 miles) southwest of Tehran. Heavy water helps cool nuclear reactors, but it produces plutonium as a byproduct that can potentially be used in nuclear weapons. That would provide Iran another path to the bomb beyond enriched uranium, should it choose to pursue the weapon. Iran had agreed under its 2015 nuclear deal with world powers to redesign the facility over proliferation concerns. The reactor became a point of contention after President Donald Trump withdrew from the nuclear deal in 2018. Ali Akbar Salehi, a high-ranking nuclear official in Iran, said in 2019 that Tehran bought extra parts to replace a portion of the reactor that it had poured concrete into to render it unusable under the deal. Israel, in conducting its strike, signaled it remained concerned the facility could be used to produce plutonium again one day. 'The strike targeted the component intended for plutonium production, in order to prevent the reactor from being restored and used for nuclear weapons development,' the Israeli military said in a statement. The International Atomic Energy Agency, the United Nations' nuclear watchdog, has been urging Israel not to strike Iranian nuclear sites. IAEA inspectors reportedly last visited Arak on May 14. Due to restrictions Iran imposed on inspectors, the IAEA has said it lost 'continuity of knowledge' about Iran's heavy water production — meaning it could not absolutely verify Tehran's production and stockpile.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store